PBS boost for melanoma patients
1 March 2020
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
All resected Stage III patients, regardless of BRAF mutation, now have subsidised access to nivolumab as adjuvant (after surgery) treatment. This is the first adjuvant immunotherapy for resected Stage III patients to be listed on the PBS, and follows clinical trials showing the therapy’s effectiveness in preventing the disease from progressing to Stage IV and spreading throughout the body.
Importantly, today’s PBS listing also includes immunotherapy as first line treatment for high risk and advanced melanoma patients who are BRAF positive. Previously, these patients were required to first undergo treatment with BRAF inhibitors and were only eligible for subsidised immunotherapy after their melanoma progressed or recurred.
Making this treatment accessible and affordable as first-line therapy for these patients will significantly increase their chances of response and long-term survival.
Today’s announcement is welcome news and a wonderful way to begin MIA's month-long awareness and fundraising campaign, Melanoma March.
‘MIA patients and their families lobbied hard for these PBS listings for many months, and this outcome is a credit to their dedication,’ said MIA Co-Medical Director Professor Richard Scolyer.
‘We thank everyone who submitted comments for consideration by the Federal Government’s PBAC, as these submissions, along with the tireless work from our team of researchers, clinicians and colleagues around the country, have now secured affordable access to these life-saving treatments for melanoma patients,’ added Co-Medical Director Professor Georgina Long.
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.